Quanterix Corporation · NASDAQ:QTRX
Quanterix — Q3 2025 Earnings Presentation
11 slides from Quanterix's earnings presentation, Nov 10, 2025
Slide 1: Third Quarter 2025 Earnings
„ Third Quarter 2025 Earnings November 10, 2025
Slide 2: Legal Information
Legal Information CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements included in this press release that are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provi
Slide 3: Q3-25: Updates from Last Quarter
Q3-25: Updates from Last Quarter Delivered on revenue expectations in a difficult environment Reported third quarter 2025 revenue of $40.2M Moving fast and capturing significant synergies through Akoya integration Greater scale establishing foundation for future growth, profitability and cash flow M
Slide 4: Synergies Leading to Cash Flow Breakeven in 2026
Synergies Leading to Cash Flow Breakeven in 2026 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Pre-close cost Complete physical Implement one • Complete all Major actions in consolidation manufacturing Systems and commercial Implement one team Financial Milestones commercial team and operations • Combine
Slide 5: Progress in Advancing Our Alzheimer's Diagnostics Business
We continue to make solid progress in advancing our Alzheimer’s Diagnostics Business Diagnostics Partner Revenue Expansion Reimbursement 5
Slide 6: Scientific Validation Driving Adoption (Pro Forma)
Scientific Validation Driving Adoption (Pro Forma) Spatial Simoa Number of Drug Trial Projects (Simoa Only) PUBLICATIONS BIOMARKERS INSTRUMENTS LAB SERVICES Cumulative Cumulative Placements Projects & Revenue ($M) # of units placed Cumulative 5,989 744 2,500 702 2,365 280 53.8 670 256 642 166 2,155
Slide 7: Q3'25 Results vs PYQ3
Q3’25 Results vs PYQ3 (in $M) Q3 GAAP Q3 Non-GAAP INSTRUMENTS CONSUMABLES ACCELERATOR OTHER 2024 2025 2024 2025 Var % Revenue Mix 18% 47% 20% 15% Revenue 35.8 40.2 35.8 40.2 12% Revenue Gross Margin $ 20.2 17.2 18.1 18.5 2% $18.8 Gross Margin % 56.3% 42.8% 50.7% 45.9% -475 bps 6.5 Operating Expense
Slide 8: 2025 Guidance
2025 Guidance Full Year Revenue: $130 to $135 million ~$30 million contribution from Spatial. Gross Margin GAAP and Adjusted Gross Margin (Non-GAAP) between 45% to 47%. $34 to $38 million of adjusted cash usage $136 million payment for Akoya and Emission acquisitions and restructuring costs, net of
Slide 9: Adjusted EBITDA (non-GAAP)
Adjusted EBITDA (non-GAAP) 9
Slide 10: Adjusted Cash Usage (non-GAAP)
Adjusted Cash Usage (non-GAAP) 10
Slide 11: Additional Non-GAAP Financial Measures
Additional Non-GAAP Financial Measures 11